Bempedoic acid and ezetimibe - better together
- PMID: 31311303
- PMCID: PMC7203625
- DOI: 10.1177/2047487319864672
Bempedoic acid and ezetimibe - better together
Conflict of interest statement
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: EDM is funded by the Blumenthal Scholars Award at Johns Hopkins University.
Comment on
-
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29. Eur J Prev Cardiol. 2020. PMID: 31357887 Free PMC article. Clinical Trial.
References
-
- Khan SU, Talluri S, Riaz H, et al. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Eur J Prev Cardiol 2018; 25: 844–853. - PubMed
-
- Sinning D and Landmesser U. Effective low-density lipo-protein-lowering therapy: Implementation in clinical practice. Eur J Prev Cardiol 2017; 24: 71–76. - PubMed
-
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459–2472. - PMC - PubMed
-
- Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA 2016; 316: 1289–1297. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical